Author information

1 Division of Gastroenterology, Michigan Medicine, 1500 East Medical Center Drive, Ann Arbor, MI 48109-5362, USA.

2 VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI 48105, USA.

Abstract

Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders encountered in clinical practice. It is a heterogeneous disorder with a multifactorial pathogenesis. Recent studies have demonstrated that an imbalance in gut bacterial communities, or "dysbiosis", may be a contributor to the pathophysiology of IBS. There is evidence to suggest that gut dysbiosis may lead to activation of the gut immune system with downstream effects on a variety of other factors of potential relevance to the pathophysiology of IBS. This review will highlight the data addressing the emerging role of the gut microbiome in the pathogenesis of IBS and review the evidence for current and future microbiome based treatments.